Brentuximab vedotin治疗CD30阳性晚期系统性肥大细胞增多症的2期研究
该2期试验评估brentuximab vedotin单药(1.8 mg/kg IV每3周,最多8周期)治疗10例CD30阳性晚期系统性肥大细胞增多症患者。按IWG-MRT-ECNM标准,无患者疗效优于疾病稳定,骨髓肥大细胞负荷、血清类胰蛋白酶及CD30表面表达均无显著下降,症状无持久改善。结论为BV单药在CD30+ advSM中无活性。
要点
- BV单药1.8 mg/kg每3周治疗CD30+晚期系统性肥大细胞增多症。
- 按IWG-MRT-ECNM标准,10例中无患者疗效优于疾病稳定。
- 骨髓肥大细胞负荷、血清类胰蛋白酶及CD30表达均无显著下降。
核心结论
- Brentuximab vedotin单药在CD30阳性晚期系统性肥大细胞增多症中无活性。
研究设计与样本
- 2期试验,纳入10例CD30+晚期系统性肥大细胞增多症患者(侵袭性SM、SM伴相关血液肿瘤或肥大细胞白血病),且至少有1项SM相关器官损害征象。
- BV单药1.8 mg/kg静脉给药,每3周1次,最多8周期。
- 主要终点为按IWG-MRT-ECNM标准评估的疗效。
主要发现
- 按IWG-MRT-ECNM标准,无患者疗效优于疾病稳定。
- 骨髓肥大细胞负荷、血清类胰蛋白酶水平及肥大细胞表面CD30表达均无显著下降。
- 自报症状评分无持久改善。
关键数值与推荐
- BV剂量为1.8 mg/kg IV,每3周1次,最多8周期。
- 疗效评估采用IWG-MRT-ECNM标准。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is an unmet need for effective therapies for advanced systemic mastocytosis (advSM). CD30 is expressed on the surface of neoplastic mast cells (MC) in more than 50% of patients with advSM. Brentuximab vedotin (BV) is a CD30-directed antibody-drug conjugate with preclinical evidence supporting both an antineoplastic effect and an attenuation of immunoglobulin E-associated mediator release. These observations are the basis for this phase 2 trial of BV monotherapy (1.8 mg/kg IV every 3 weeks up to 8 cycles) in patients with CD30-positive advSM. The primary objective was to determine the efficacy of BV according to International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis (IWG-MRT-ECNM) response criteria. Secondary objectives included evaluation of safety, changes in bone marrow (BM) MC burden, serum tryptase level, flow cytometric quantification of MC surface expression of CD30, and self-reported symptom burden. The trial enrolled 10 patients with a diagnosis of CD30+ advSM (aggressive SM, SM with an associated hematologic neoplasm [SM-AHN], or mast cell leukemia [MCL]) with 1 or more signs of SM-related organ damage. According to IWG-MRT-ECNM criteria, none of the patients demonstrated better than stable disease with BV. In addition, there were no significant reductions in BM MC burden, serum tryptase levels, or MC surface expression of CD30. Self-reported symptom scores showed no durable improvement with BV treatment. We conclude that BV is not active as a single agent in CD30+ advSM. This trial was registered at www.clinicaltrials.gov as #NCT01807598.
引用
- Gotlib J, Baird JH, George TI, et al. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv. 2019. PMID: 31350306. doi:10.1182/bloodadvances.2019000152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。